Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Fundamental & Clinical Pharmacology|February 22, 2019
A population analysis of the DGAT1 inhibitor GSK3008356 and its effect on endogenous and meal-induced triglyceride turnover in healthy subjectsMalek Okour, Richard A Brigandi, David Tenero
Current Opinion in Pharmacology|May 14, 2004
Emerging therapeutic targets in psoriasisAndrew I Bayliffe, Richard A Brigandi, H Jeffrey Wilkins, et al.
Clinical Pharmacology in Drug Development|January 17, 2019
A Phase 1 Randomized, Placebo-Controlled Trial With a Topical Inhibitor of Stearoyl-Coenzyme A Desaturase 1 Under Occluded and Nonoccluded ConditionsRichard A Brigandi, John Zhu, Amy A Murnane, et al.
Clinical Pharmacology in Drug Development|April 6, 2019
First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy VolunteersMalek Okour, Angela Gress, Xinyi Zhu, et al.
Clinical Pharmacology in Drug Development|June 23, 2015
Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7-β-Cyclodextrin Formulation of the Neurokinin-1 Receptor Antagonist VestipitantRichard A Brigandi, Steven F Russ, Chantal Petit, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 1, 2016
A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized TrialRichard A Brigandi, Brendan Johnson, Coreen Oei, et al.
Pageof 1